MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

NCT04110301 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma and Marginal Zone Lymphoma

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL62 Injection
DRUG: Lenalidomide

Sponsor

Beijing Mabworks Biotech Co., Ltd.